ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pacritinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

30 träffar

Bibliografisk träff 2024-04-22

miR-146a<sup>-/-</sup> mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype.

Cuenca-Zamora EJ, Guijarro-Carrillo PJ, López-Poveda MJ, Morales ML, Lozano ML, Gonzalez-Conejero R, Martínez C, Teruel-Montoya R, Ferrer-Marín F.

Am J Hematol · research support, non-u.s. gov't; journal article · DOI 10.1002/ajh.27322

Bibliografisk träff 2024-04-01

<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO.

Haematologica · published erratum; correction; journal article · DOI 10.3324/haematol.2023.284815

Bibliografisk träff 2024-02-19

Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines.

Wu Y, Wang V, Yarchoan R.

Sci Rep · research-article; journal article · DOI 10.1038/s41598-024-54453-7

Bibliografisk träff 2024-01-02

Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.

Tefferi A, Pardanani A, Gangat N.

Am J Hematol · review; journal article · DOI 10.1002/ajh.27163

Bibliografisk träff 2024-01-01

Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.

Handa S, Farina KA, Becker M, Kelly B, Yu A, Feld J, Tremblay D, Marcellino BK, Salib C, Mascarenhas J, Shih AH.

JCO Precis Oncol · journal article; case reports; case-report · DOI 10.1200/po.23.00234

Bibliografisk träff 2023-12-28

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.

Duminuco A, Chifotides HT, Giallongo S, Giallongo C, Tibullo D, Palumbo GA.

Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers16010154

Bibliografisk träff 2023-11-02

Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.

Mao F, Gao L, Liu L, Tang Y.

J Chemother · journal article · DOI 10.1080/1120009x.2023.2274700

Bibliografisk träff 2023-11-01

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.

Tefferi A, Pardanani A, Gangat N.

Haematologica · research-article; journal article · DOI 10.3324/haematol.2022.282612

Bibliografisk träff 2023-10-01

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.

Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S.

Blood Adv · research-article; journal article · DOI 10.1182/bloodadvances.2023010151

Bibliografisk träff 2023-07-01

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.

Harrison C, Yacoub A, Scott B, Mead A, Gerds AT, Kiladjian JJ, Mesa R, Egyed M, Scheid C, Gutierrez VG, O'Sullivan J, Buckley S, Kanellopoulos K, Mascarenhas J.

Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2022.282089

Bibliografisk träff 2023-06-01

Pacritinib and its use in myelofibrosis associated thrombocytopenia.

Qureshi FA, Zulfi MH, Abbas Z.

J Pak Med Assoc · letter · DOI 10.47391/jpma.8024

Bibliografisk träff 2023-05-19

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms.

Kong T, Yu L, Laranjeira ABA, Fisher DAC, He F, Cox MJ, Oh ST.

Am J Hematol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/ajh.26935

Bibliografisk träff 2023-03-19

Pharmacotherapeutic advances for splenomegaly in myelofibrosis.

Tremblay D, Mascarenhas J.

Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2023.2192350

Bibliografisk träff 2023-02-01

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice.

Petrova T, Figueras-Vadillo C, Nanda SK, Scudamore C, Cohen P.

Lupus Sci Med · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1136/lupus-2022-000822

Bibliografisk träff 2023-01-25

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3.

Ghezzi C, Chen BY, Damoiseaux R, Clark PM.

Sci Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-023-28576-2

Bibliografisk träff 2023-01-01

First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.

De SK.

Anticancer Agents Med Chem · journal article · DOI 10.2174/1871520623666230320120915

Bibliografisk träff 2022-12-01

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.

Cafardi J, Miller C, Terebelo H, Tewell C, Benzaquen S, Park D, Egan P, Lebovic D, Pettit K, Whitman E, Tremblay D, Feld J, Buckley S, Roman-Torres K, Smith J, Craig A, Mascarenhas J.

JAMA Netw Open · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1001/jamanetworkopen.2022.42918

Bibliografisk träff 2022-12-01

Pacritinib for myelofibrosis in adults with thrombocytopenia.

Yang DH, Lu Q, Zhu Z, Huang G, Young K.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2022.58.12.3474538

Bibliografisk träff 2022-10-20

Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.

Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A.

EJHaem · research-article; journal article · DOI 10.1002/jha2.591

Bibliografisk träff 2022-10-13

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.

Torres S, Ortiz C, Bachtler N, Gu W, Grünewald LD, Kraus N, Schierwagen R, Hieber C, Meier C, Tyc O, Joseph Brol M, Uschner FE, Nijmeijer B, Welsch C, Berres ML, Garcia-Ruiz C, Fernandez-Checa JC, Trautwein C, Vogl TJ, Zeuzem S, Trebicka J, Klein S.

Hepatology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/hep.32746

Bibliografisk träff 2022-08-01

The odyssey of pacritinib in myelofibrosis.

Venugopal S, Mascarenhas J.

Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2022007524

Bibliografisk träff 2022-08-01

Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.

Mascarenhas J.

Expert Rev Hematol · research support, non-u.s. gov't; review; journal article · DOI 10.1080/17474086.2022.2112565

Bibliografisk träff 2022-07-18

Pacritinib

Författaruppgift saknas

Tidskrift saknas · review

Bibliografisk träff 2022-07-01

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO.

Haematologica · research support, non-u.s. gov't; journal article · DOI 10.3324/haematol.2021.279415

Bibliografisk träff 2022-05-01

Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance.

Oh Y, Lee JS, Lee JS, Park JH, Kim HS, Yoon S.

Anticancer Res · journal article · DOI 10.21873/anticanres.15722

Bibliografisk träff 2022-05-01

Pacritinib: First Approval.

Lamb YN.

Drugs · review; journal article · DOI 10.1007/s40265-022-01718-y

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2016-09-21

The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.

Jain T, Mesa R.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1080/14737140.2016.1233061

Bibliografisk träff 2014-08-19

Profile of pacritinib and its potential in the treatment of hematologic disorders.

Hatzimichael E, Tsolas E, Briasoulis E.

J Blood Med · review-article; review; journal article · DOI 10.2147/jbm.s51253

Bibliografisk träff 2011-06-15

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.

William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.

J Med Chem · journal article · DOI 10.1021/jm200326p